AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
SALVATORI OPHTHALMICS INC
Q · usd
SIC 3845 · ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
FIGI AK-C4214C2142
30.49▲ 0.46 (1.53%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
30.04
Day's Range
30.33 – 30.49
52-Week Range
23.90 – 30.49
Volume
356
Avg Volume
652
Share Statistics
Shares Outstanding
Employees
—
Exchange
Q
Listed
—
Share count as of August 13, 2026

SALVATORI OPHTHALMICS INC (EYES) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about SALVATORI OPHTHALMICS INC (EYES)
What is SALVATORI OPHTHALMICS INC's Market Cap?
SALVATORI OPHTHALMICS INC's Market Cap is $2.8B, based on as-reported figures from SEC (XBRL) filings.
What is SALVATORI OPHTHALMICS INC's Revenue (TTM)?
SALVATORI OPHTHALMICS INC's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is SALVATORI OPHTHALMICS INC's Net Income (TTM)?
SALVATORI OPHTHALMICS INC's Net Income (TTM) is -$26.3M, based on as-reported figures from SEC (XBRL) filings.
What is SALVATORI OPHTHALMICS INC's EBITDA?
SALVATORI OPHTHALMICS INC's EBITDA is -$26.9M, based on as-reported figures from SEC (XBRL) filings.
What is SALVATORI OPHTHALMICS INC's Diluted EPS (TTM)?
SALVATORI OPHTHALMICS INC's Diluted EPS (TTM) is -0.29, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · EYESAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Operating expenses:
Research and development, net of grants
General and administrative, net of grants
Total operating expenses
Loss from operations
Other income, net
Net loss
Net loss per common share - basic (in dollars per share)
Net loss per common share - diluted (in dollars per share)